Iovance Biotherapeutics Announces Preliminary Phase 2 Data for TIL Treatment in Head and Neck and Cervical Cancers

Iovance Biotherapeutics (Nasdaq:IOVA) a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte technology, today reported preliminary clinical results from two ongoing open-label Phase 2 studies in head and neck and cervical cancers.
As quoted in the press release:

Three of the eight patients treated with LN-145 had a reduction in tumor size of at least 30% and qualified as a Partial Response (PR) as per RECIST 1.1 criteria. The Objective Response Rate (ORR) in the study is 38% to date. These patients had a median of 4 prior treatments for their cancer and had all received prior anti-PD-1 therapy. Two of eight had also received prior anti-CTLA-4. The most common side effects were pyrexia, chills, and hypotension. Iovance will continue to enroll patients in this study to the full sample size of 47 per protocol.

Click here to read the full press release.